StockData
Gilead Sciences, Inc. logo

Gilead Sciences, Inc.

GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.33−0.35 (-0.21%)

Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%

Gilead Sciences Tecartus (brexucabtagene autoleucel by Quarter

Tecartus (brexucabtagene autoleucel — MCL / ALL CAR T) — Europe sales ($M) ($M)

QuarterlyAnnual

Gilead Sciences Tecartus (brexucabtagene autoleucel: $34M in Q2 2026, down 17.1% from a year earlier.

Latest, Q2 2026
34
Period ended Jun 30, 2026
Change on a year earlier
-17.1%
41 in Q2 2025
History
27 quarters
Since Q4 2019
Sources
22
Documents cited below

Where the Q2 2026 figure comes from

Source: Form 10-Q (filed 2026-08-06) ↗

Reported in Form 10-Q / 10-K Disaggregated Revenue Note & Form 8-K Product Sales Summary.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedTecartus (brexucabtagene autoleucel — MCL / ALL CAR T) — Europe sales ($M) ($M)Year on yearSource
Q2 2026Jun 30, 202634-17.1%Form 10-Q (filed 2026-08-06) ↗
Q1 2026Mar 31, 202637+19.4%Form 10-Q (filed 2026-05-07) ↗
Q4 2025Dec 31, 202551+41.7%Form 10-K (filed 2026-02-24) ↗
Q3 2025Sep 30, 202535+20.7%Form 10-Q (filed 2025-11-07) ↗
Q2 2025Jun 30, 202541+10.8%Form 10-Q (filed 2026-08-06) ↗
Q1 2025Mar 31, 202531-13.9%Form 10-Q (filed 2026-05-07) ↗
Q4 2024Dec 31, 202436+33.3%Form 10-K (filed 2026-02-24) ↗
Q3 2024Sep 30, 202429+7.4%Form 10-Q (filed 2025-11-07) ↗
Q2 2024Jun 30, 202437+27.6%Form 10-Q (filed 2025-08-07) ↗
Q1 2024Mar 31, 202436+33.3%Form 10-Q (filed 2025-05-07) ↗
Q4 2023Dec 31, 202327+42.1%Form 10-K (filed 2026-02-24) ↗
Q3 2023Sep 30, 202327+35.0%Form 10-Q (filed 2024-11-12) ↗
Q2 2023Jun 30, 202329+45.0%Form 10-Q (filed 2024-08-08) ↗
Q1 2023Mar 31, 202327+80.0%Form 10-Q (filed 2024-05-08) ↗
Q4 2022Dec 31, 202219+26.7%Form 10-K (filed 2025-02-28) ↗
Q3 2022Sep 30, 202220+66.7%Form 10-Q (filed 2023-11-07) ↗

Cite this data

StockData. (2026). Gilead Sciences Tecartus (brexucabtagene autoleucel ($M), quarterly Q4 2019–Q2 2026 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/onc-tecartus-eu

See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.